Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List

Innovent expands NRDL coverage to 17 drugs, now reaching over 20 million patients in China.

What the company is saying

Innovent Biologics, led by Founder, Chairman, and CEO Dr. Michael Yu, is highlighting the successful inclusion of seven innovative products in China's updated 2026 National Reimbursement Drug List (NRDL), effective January 1, 2027. The announcement emphasizes the breadth of disease coverage—oncology, cardiovascular, metabolic, and autoimmune—and frames the inclusion as a major step in improving accessibility and affordability for patients. The company claims its NRDL-covered lineup now totals 17 drugs, cumulatively benefiting over 20 million patients. Innovent underscores the uniqueness of its products, such as mazdutide being the first and only approved GCG/GLP-1 dual receptor agonist globally, and picankibart achieving a PASI 90 response rate exceeding 80% at 16 weeks. The release also spotlights strategic partnerships with global pharmaceutical leaders, stating an aggregate value of over RMB 350 billion. The tone is confident and forward-looking, positioning Innovent as a leader in China's biopharmaceutical industry and aligning its mission with national health strategies.

What the data suggests

The update confirms seven Innovent products—mazdutide, PECONDLE® (picankibart), TABOSUN® (Ipilimumab N01), Vanflyta® (quizartinib), TYVYT® (sintilimab), Jaypirca® (pirtobrutinib), and SINTBILO® (tafolecimab)—are now included or renewed in the 2026 NRDL, with effect from January 1, 2027. This brings the total number of Innovent drugs covered by the NRDL to 17. The company reports that its NRDL-listed drugs have benefited over 20 million patients cumulatively. Picankibart is highlighted for achieving a PASI 90 response rate exceeding 80% at 16 weeks in Phase III trials, and Jaypirca is noted as being 300 times more selective for BTK versus 98% of other kinases tested. Innovent has launched 20 products, has 1 asset under NMPA review, 6 assets in phase 3 or pivotal clinical trials, and 20 molecules in early clinical stage. Over 30 strategic partnerships have been formed, with an aggregate value exceeding RMB 350 billion. While these figures demonstrate operational scale and pipeline breadth, the announcement does not disclose revenue, profit, or period-over-period financial performance, so the direct financial impact of these milestones remains unquantified.

Analysis

The announcement is upbeat, highlighting the successful inclusion of seven products in the 2026 NRDL and the expansion to 17 covered drugs, with over 20 million cumulative patients benefited. These are realised, operational milestones, not mere projections. However, the tone is somewhat inflated by repeated references to being 'first and only' and by emphasizing the aggregate value of strategic partnerships (RMB 350 billion) without clarifying the direct financial impact or revenue contribution. The most forward-looking claim is that the NRDL update will take effect on January 1, 2027, which is over a year away, making the execution distance long-term for new reimbursement-driven revenue. No profitability, revenue, or cash flow metrics are disclosed, so the true_signal cannot exceed weak_positive. The capital intensity flag is not triggered, as no new large capital outlay is announced. The gap between narrative and evidence lies in the lack of financial data and the promotional framing of partnership values and product 'firsts' without substantiating their commercial impact.

Risk flags

• ●The absence of financial data—such as revenue, profit, or cash flow attributable to the NRDL inclusions—prevents investors from assessing the direct commercial impact of these milestones. This limits transparency on how operational achievements translate into financial performance.
• ●The company's claims of being 'first and only' for several products, and the aggregate partnership value of over RMB 350 billion, are not substantiated with supporting data on market share, regulatory status, or attributable revenue, raising the risk of promotional overstatement.
• ●Realization of the projected patient and commercial benefits depends on the actual uptake of the newly listed drugs post-January 2027, which is subject to market dynamics, competition, and reimbursement execution.
• ●The company's large pipeline and partnership network imply significant ongoing R&D and commercialization costs, but no disclosure is provided on capital requirements or funding sufficiency, introducing potential financial risk if future cash flows do not materialize as expected.

Bottom line

Innovent's successful expansion to 17 NRDL-listed drugs, now reaching over 20 million patients, marks a major operational milestone and positions the company as a key player in China's biopharmaceutical market. The inclusion of high-profile products and new indications should enhance market access and could drive future revenue, but the announcement does not provide any direct financial metrics or guidance. The company's emphasis on unique product attributes and large partnership values is not matched by evidence of commercial outcomes or profitability. Investors should recognize that while NRDL inclusion is a critical prerequisite for scale in China, the actual financial impact will depend on market uptake after January 2027. The most important takeaway is that Innovent has secured a strong reimbursement platform, but the absence of financial disclosure means the investment case rests on future execution and market adoption.

Announcement summary

(HKEX:01801) Innovent Biologics, Inc. announced that seven of its innovative products have been successfully included in the updated National Reimbursement Drug List (NRDL) for 2026 in China. The products newly included in the NRDL are mazdutide (a GCG/GLP-1 dual receptor agonist), PECONDLE® (picankibart injection, an IL-23p19 inhibitor), TABOSUN® (Ipilimumab N01 injection, a CTLA-4 inhibitor), and Vanflyta® (quizartinib, a Type II FLT3 inhibitor). Products with newly added indications in the NRDL are TYVYT® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jaypirca® (pirtobrutinib, a non-covalent BTK inhibitor), while SINTBILO® (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The updated NRDL will take effect from January 1, 2027. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated that the inclusion covers disease areas such as oncology (colon cancer, renal cancer, hematological malignancies), cardiovascular and metabolic diseases, and autoimmune diseases, and will enhance accessibility and affordability for patients. With this update, Innovent's innovative drugs covered by the NRDL have expanded to 17, cumulatively benefiting over 20 million patients. Mazdutide is the first and only approved GCG/GLP-1 dual receptor agonist globally and is included for type 2 diabetes in adults. PECONDLE® (picankibart injection) is the first and only domestic IL-23p19 inhibitor and achieved a PASI 90 response rate exceeding 80% at 16 weeks in a Phase III trial, with the longest maintenance dosing interval in its class (once every 12 weeks). TABOSUN® (Ipilimumab N01 injection) is included for use in combination with sintilimab for neoadjuvant treatment of resectable stage IIB-III MSI-H or dMMR colon cancer, representing the world's only approved dual-immunotherapy combination regimen for this indication. Vanflyta® (quizartinib) is included for newly diagnosed FLT3-ITD positive acute myeloid leukemia. TYVYT® (sintilimab injection) now has two additional indications included: in combination with ipilimumab N01 for neoadjuvant treatment of MSI-H/dMMR colon cancer, and in combination with fruquintinib for second-line renal cell carcinoma. Jaypirca® (pirtobrutinib) is included for adult patients with CLL/SLL who have received at least one prior systemic therapy including a BTK inhibitor, and is 300 times more selective for BTK versus 98% of other kinases tested. SINTBILO® (tafolecimab injection) was approved in August 2023 and included in the NRDL on January 1, 2025, with the renewal further alleviating patient financial burden. Innovent has launched 20 products, has 1 asset under NMPA review, 6 assets in phase 3 or pivotal clinical trials, and 20 molecules in early clinical stage. The company has entered into more than 30 strategic partnerships with global players, representing an aggregate value of over RMB 350 billion. Innovent's NRDL lineup now covers 17 innovative drugs, cumulatively benefiting over 20 million patients.

Disagree with this article?